In the media
July 1, 2020
Owkin rounds out its series A with another $18M in capital
About Owkin
Owkin is an agentic AI company pioneering Biological Artificial Superintelligence to solve problems in biology too challenging for human researchers alone.
Owkin builds K Pro - an AI scientist that works alongside pharmaceutical research teams to power discovery and strategic decision-making. K Pro autonomously orchestrates a suite of AI skills and tools to decode complex biology and accelerate research, with scientists shaping every hypothesis, decision, and discovery.
K Pro is built on Owkin’s unrivalled multimodal patient data network, state-of-the-art AI for biology, and a decade of experience working hand-in-hand with pharmaceutical partners.